BioLitec AG

28.10.2010 – 10:35
EANS-News: biolitec´s cancer therapy successful with Foscan® - PDT-drug has a positive effect in two thirds of the "hopeless cases" - Free of charge treatment in the Netherlands
A European clinical multicenter study shows that 68% of the patients treated with photodynamic therapy (PDT) using biolitecs cancer drug Foscan® responded well 27% chance of living tumor-free for five years or more Free of charge treatment in the Netherlands possible now Corporate news transmitted ...
mehr
30.09.2008 – 12:41
biolitec AG achieved consolidated revenue of Euro 35.4 million for the fiscal year 2007/2008 -expectation of sales growth to resume in this fiscal year
R&D expenditures with Euro 5.1 million remained at a high level urology and aesthetic laser therapy remain growth markets strongest urology laser worldwide already in use in Germany ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this ...
mehr
29.02.2008 – 14:48
biolitec AG continues strong revenue and profit growth in the first half of the year - EBIT growth of 23 % up to Euro 3.0 million - BPH laser were placed in the market as planned
Again record profits in the first six months of fiscal year 2007/2008 Innovative laser therapy LIFE for the treatment of enlarged prostate (BPH) and revolutionary vein treatment pro-cedure ELVeS are biggest revenue driver Group turnover increases by 12 % up to Euro 19.1 million ots.CorporateNews ...
mehr